Abstract: PUB332
Incidence Rate of Catheter-Related Bloodstream Infection After Solid-Organ Transplant: A Single-Center Experience
Session Information
Category: Transplantation
- 2102 Transplantation: Clinical
Authors
- El Mouhayyar, Christopher, Massachusetts General Hospital, Boston, Massachusetts, United States
- Al Jurdi, Ayman, Massachusetts General Hospital, Boston, Massachusetts, United States
- Safa, Kassem, Massachusetts General Hospital, Boston, Massachusetts, United States
Background
Catheter-related bloodstream infections (CRBSI) incidence is well-studied in general hemodialysis patients. There is a lack of data on CRBSI rates specifically in solid organ transplant (SOT) recipients requiring hemodialysis. This study aims to investigate CRBSI incidence in this population at a single center.
Methods
This retrospective, single-center cohort study at Massachusetts General Hospital (MGH) investigated CRBSI incidence in non-kidney SOT (i.e., heart, lung, liver) who required hemodialysis (HD) via a tunneled dialysis catheter (TDC) between January 2016 and October 2024. EMR data was utilized to identify adults aged ≥18 who underwent non-kidney SOT and developed renal failure requiring TDC-based HD.
Results
42 individuals met our inclusion criteria. The mean age of this cohort was 57 years, 50% were male, and 81% were White. The group consisted of 17 liver transplant recipients (40.5%), 13 heart transplant recipients (31.0%), and 12 lung transplant recipients (28.6%). None of the heart or liver transplant recipients received antibody induction therapy while 8 lung recipients received basiliximab induction, and 4 received no induction therapy. 97% of the patients received mycophenolate mofetil, tacrolimus, and prednisone, while 3% received steroid-free maintenance. The median follow-up was 51.5 days (interquartile range 16-233). During this period, 6 individuals developed CRBSI, resulting in an incidence rate of 0.86 infections per 1000 catheter-days. No deaths were attributed to CRBSI.
Conclusion
Our findings suggest that immunosuppression in the setting of SOT is not associated with an increased risk of CRBSI in patients with renal failure utilizing TDCs especially when a consistent and standardized protocol for the access and care of these catheters is utilized.